CLOs on the Move

Groupe Parima

www.groupeparima.com

 
Groupe Parima is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

KBP Biosciences

At KBP we are consistently reminded that patient care is the end goal of what we do daily.

Aphria Incorporated

Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible.

Shoppers Drug Mart

Built on a foundation of professional expertise and personal service, Shoppers Drug Mart has been meeting Canadians` health care needs for 50 years. What was once a small pharmacy in Toronto has grown into an organization of over 1,200 stores from coast to coast, becoming an indelible part of the lives of Canadians, young and old. Yet despite our growth, we have never forgotten our origins. We have always remained true to our belief that the personal satisfaction of each and every customer is at the root of our success - and it can only be ensured by the commitment of people who realize that success is built one customer at a time.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.